5.2.7.2. α1-blockers + muscarinic receptor antagonists. mechanism action: combination treatment consists α1-blocker together antimuscarinic aiming antagonise α1-adrenoceptors muscarinic receptors. possible combinations tested clinical trials date. efficacy: several rcts prospective studies investigated combination therapy, lasting four twelve weeks, either initial treatment men oab presumed bpo sequential treatment storage symptoms persisting α1-blocker [212,223,287,292-296]. combination treatment marginal efficacy reducing urgency, uui, voiding frequency, nocturia, ipss compared α1-blockers placebo alone, improves qol . sr meta-analysis rcts (six studies treatment-naïve patients, five studies men persistent storage luts despite prior treatment α-blockers) concluded addition antimuscarinics α-blockers marginally reduced number micturition episodes per day (standard mean difference -0.19) significant impact number urgency episodes, higher side effect profile . similar findings also reported cochrane review rcts men luts secondary bpo, small improvement ipss (mean difference 2.04) qol (mean difference 0.71) combination therapy compared α-blocker monotherapy, although overall certainty evidence deemed moderate low . symptom improvement higher regardless psa concentration combination therapy, whereas tolterodine alone improved symptoms mainly men serum psa < 1.3 ng/ml . meta-analysis sixteen studies 3,548 patients bph/oab, initial combination treatment α1-blocker anticholinergic medication showed difference total ipss qmax two groups . effectiveness therapy evident primarily men moderate-to-severe storage luts . long term use combination therapy reported patients receiving treatment one year, showing symptomatic response maintained, low incidence aur . men moderate-to-severe storage symptoms, voiding symptoms pvr < 150 ml, reduction symptoms using combination therapy associated patient-relevant improvements health related qol compared placebo α1-blocker monotherapy . combined behavioural drug therapy yielded greater improvements oab symptoms drug therapy alone, behavioural therapy alone rct evaluating effectiveness combined behavioural strategies drug therapy oab symptoms men . tolerability safety: adverse events drug classes seen combined treatment using α1-blockers antimuscarinics. common side-effect dry mouth. side-effects (e.g. dry mouth ejaculation failure) may show increased incidence cannot simply explained summing incidence drugs used separately. increased pvr may seen, usually clinically significant, risk aur low one year treatment . antimuscarinics cause evident deterioration qmax used conjunction α1-blocker men oab symptoms . rct investigated safety terms maximum detrusor pressure qmax solifenacin (6 mg 9 mg) tamsulosin men luts boo compared placebo . combination therapy non-inferior placebo primary urodynamic variables; qmax increased vs. placebo . practical considerations: class effects likely underlie efficacy qol using α1-blocker antimuscarinic. trials used mainly storage symptom endpoints, short duration, included men low pvr volumes baseline. therefore, measuring pvr recommended combination treatment. summary evidencelecombination treatment α1-blockers antimuscarinics effective improving luts-related qol impairment.2combination treatment α1-blockers antimuscarinics effective reducing urgency, uui, voiding frequency, nocturia, ipss compared α1-blockers placebo alone.2adverse events drug classes seen combined treatment using α1-blockers antimuscarinics.1there low risk aur using α1-blockers antimuscarinics men known pvr volume < 150 ml.2 recommendationsstrength ratinguse combination treatment α1-blocker muscarinic receptor antagonist patients moderate-to-severe luts relief storage symptoms insufficient monotherapy either drug.weakdo prescribe combination treatment men post-void residual volume > 150 ml.weak